Since joining Kirkland, Benjamin has been involved in the following matters:
- Akero Therapeutics in its sale to Novo Nordisk for up to $5.2 billion
Prior to joining Kirkland, Benjamin was involved in the following representative matters:
- SiteOne Therapeutics in its pending acquisition by Eli Lilly for up to $1 billion
- AspenTech in its $11 billion combination with the industrial software business of Emerson Electric and the special committee in its subsequent $7.2 billion sale to Emerson of all shares of AspenTech not already owned by Emerson
- The special committee of the board of directors of R1 RCM in its sale to investment funds affiliated with TowerBrook Capital Partners and Clayton Dubilier & Rice for an enterprise value of $8.9 billion
- EyeBio in its sale to Merck for $1.3 billion up front and up to $1.7 billion in future milestone payments
- Mirati Therapeutics in its sale to Bristol Myers Squibb for up to $5.8 billion
- Intercept Pharmaceuticals in its sale to Alfasigma for approximately $800 million
- BELLUS Health in its $2 billion sale to GSK
- Ambrx Biopharma in its $2 billion acquisition by Johnson & Johnson
- Alcon in its $753 million acquisition of Aerie Pharmaceuticals
- Strongbridge Biopharma in its sale to Xeris Pharmaceuticals for $267 million
- Pandion Therapeutics in its sale to Merck & Co. for $1.85 billion
- Stemline Therapeutics in its sale to Menarini Group for up to $677 million
- Ionis Pharmaceuticals in its acquisition of the remaining outstanding stake of Akcea Therapeutics for $500 million
- Gilead Sciences in its $4.9 billion acquisition of Forty Seven
- Alder BioPharmaceuticals in its sale to Lundbeck for up to $1.95 billion
